Eris Lifesciences Limited (NSEI:ERIS) entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion on November 08, 2023. Post deal close, over 120 employees of the two business units are expected to transition to Eris, ensuring continuity for both employees and patients. The Dermatology and Nephrology branded formulations business units reported revenues of INR 900 million and net worth of INR 250 million in FY 2022-23. The deal is subject to customary closing conditions and is expected to close by the end of Nov 2023.

Eris Lifesciences Limited (NSEI:ERIS) completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics on November 10, 2023. Nivedita Tiwari, Shailesh Singh, Anupama Singh, Pooja Ramchandani, Suruchi Kumar, Apoorva Murali, Neha Khanduri, Amit Singhania, Ankita Bhasin, Rahul Yadav, Harman Singh Sandhu and Raveena Kumari Sethia of Shardul Amarchand Mangaldas & Co acted as the legal advisors to Eris Lifesciences. Cyril Amarchand Mangaldas acted as the legal advisor to Biocon Biologics.